Loading clinical trials...
Loading clinical trials...
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis
Conditions
Interventions
Ruxolitinib
9-ING-41
Locations
9
United States
University of Southern California
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
Georgia Cancer Center
Augusta, Georgia, United States
Mayo Clinic
Rochester, Minnesota, United States
Siteman Cancer Center
St Louis, Missouri, United States
Weill Cornell Medicine | NewYork-Presbyterian Meyer Cancer Center
New York, New York, United States
Start Date
August 20, 2020
Primary Completion Date
October 13, 2022
Completion Date
January 18, 2024
Last Updated
February 7, 2024
NCT06859424
NCT06343805
NCT05123365
NCT07104799
NCT05037760
NCT06164561
Lead Sponsor
Actuate Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions